Traveller’s diarrhoea is common in people travelling abroad and military personnel stationed overseas. Image credit: Shutterstock/litabit

Immuron has kickstarted its Phase II trial investigating the efficacy of its tablet for infectious diarrhoea caused by Enterotoxigenic Escherichia coli (ETEC).

Also known as Travellers’ diarrhoea, the condition is often experienced by individuals visiting foreign countries and is contracted by eating contaminated food or water.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Australian biopharma company Immuron is conducting a trial (NCT05933525) comparing its candidate Travelan (IMM-124E) against a placebo after challenge with an ETEC strain. The company has completed the first cohort enrolment of 30 participants. A second cohort of 30 patients is expected to be enrolled by October 2023.

Dosing and the in-patient stage of the study’s first cohort are expected to be completed by the first week of August 2023. Headline results from the clinical trial are expected in the first half of 2024. 

Immuron’s treatment aims to prevent the infection as opposed to treating it once symptoms have started. Participants will begin the regimen two days prior to the ETEC challenge. Six Travelan tablets (1200mg) will be orally administered over seven days.

Participants will also be given ciprofloxacin 500 mg by mouth twice daily for three days – standard of care treatment – five days after the challenge unless early treatment criteria are met.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary endpoint measuring the efficacy is the number of subjects to encounter moderate to severe diarrhoea. Each patient’s stool sample will be graded by how watery it is.

Travellers’ diarrhoea is also common amongst military personnel stationed in overseas countries. The US Department of Defense Uniformed Services University is also running its own randomised clinical trial (NCT04605783) with Travelan in up to 868 participants.